Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
The Pharma Letter20h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II
BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...
BridgeBio price target raised to $46 from $45 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...
Q3 Earnings Forecast for BBIO Issued By Leerink Partnrs
Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.
BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts
We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...
marketinference6d
Analyzing the Reasons Behind BBIO's Stock Decline
BridgeBio Pharma stock is trading -36.77% below its average target price of $52.27 after dropping -8.8% during today's ...
Investing7d
BridgeBio stock falls on convertible notes offering
Investing.com -- Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) dipped 3% in after-hours trading on Monday following the company's announcement of a proposed offering of convertible senior notes to ...
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...
Peninsula drugmaker nails heart failure drug launch in battle with Big Pharma
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $52.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Scotiabank from $49.00 to $52.00 in a research ...
Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...